Crinetics Pharmaceuticals, Inc. (CRNX)股价表现 - Crinetics Pharmaceuticals, Inc. (CRNX)股价在最近一个交易日上涨了19.1%，收于45.18美元[1] PATHFNDR-2研究结果 - Crinetics公司在第二个晚期研究（PATHFNDR-2）中取得了主要和所有关键次要终点，具有统计学意义，评估了其主力候选药物paltusotine治疗肢端肥大症的疗效和安全性，这导致了股价的突然上涨[2] 财报预期 - Crinetics公司预计在即将发布的财报中每股亏损0.84美元，同比增长1.2%，预计营收为820万美元，较去年同期下降了69.6%[3] 盈利预期调整 - Crinetics Pharmaceuticals的每股盈利预期在过去30天内上调了5.5%，这种正面的盈利预期趋势通常会转化为股价上涨[5]

Crinetics Pharmaceuticals新闻 - Crinetics Pharmaceuticals宣布了来自PATHFNDR-2的积极的头条结果，该研究是评估口服一次日服用的研究性药物paltusotine治疗肢端肥大症的两项第三阶段研究之一[1] - PATHFNDR-2研究结果显示，paltusotine在治疗肢端肥大症患者中表现出显著的疗效和安全性，且未出现严重不良事件[2] - Crinetics计划在2024年下半年向FDA提交NDA，为paltusotine的批准提供支持，以及为2025年的上市做准备[3]

paltusotine研究结果 - Crinetics Pharmaceuticals宣布了paltusotine在第二期类癌综合症研究中的积极结果[1] - paltusotine在研究中表现出快速和持续减少潮红发作和排便次数的效果[3] - paltusotine是第一种口服、每日一次的选择性靶向生长抑素受体2（SST2）激动剂，目前正在进行乳腺肥大症的第三期临床研究和类癌综合症的第二期临床研究[7]

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options were granted as inducements material to th ...

koya79 Financial and Clinical Progress Positions Crinetics for Market Leadership Much has changed at Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) since my first look nearly a year ago. Back then, I expressed concern over their oral solution for acromegaly and made the argument that paltusotine, by the nature of its oral administration, would likely not be able to replicate the efficacy and safety of existing subcutaneous drugs like octreotide. Nonetheless, I did recognize the potential of Crinetics' dr ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Scott Struthers - Founder and Chief Executive Officer Alan Krasner - Chief Endocrinologist Marc Wilson - Chief Financial Officer Jim Hassard - Chief Commercial Officer Conference Call Participants Joseph Schwartz - Leerink Partners Yasmeen Rahimi - Piper Sandler Jeff Hung - Morgan Stanley Cory Jubinville - LifeSci Brian Skorney - Baird Douglas Tsao - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-3744114 (State or other juris ...

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics" or the "Company"), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors in an oversubscr ...

EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024 Phase 2 Study of Paltusotine in Carcinoid Syndrome Full Topline Results Expected 1H 2024 Announced a $350 Million Private Placement Equity Financing Management Hosting Conference Call and Webcast at 4:30 p.m. ET Today SAN DIEGO – February 28, 2024 – Cr ...

公司薪酬奖励 - Crinetics Pharmaceuticals, Inc.宣布董事会薪酬委员会授予了九名新的非执行员工73,000股普通股的非合格股票期权奖励[1] - 期权的行权价格为每股39.46美元，与2024年2月9日在纳斯达克全球精选市场上Crinetics的普通股收盘价相等[3] 公司背景介绍 - Crinetics Pharmaceuticals是一家临床阶段的制药公司，专注于发现、开发和商业化用于内分泌疾病和内分泌相关肿瘤的新型治疗药物[5]